AlloVir, Inc. (ALVR): Rasio rega marang prakiraan pendapatan

AlloVir, Inc. (ALVR) aims to secure a dominant position in the cell therapy niche by outpacing competitors in regulatory matters. The projected P/S ratio on this GURU.Markets chart indicates that the metric remains around . The business relies on external CRO/CMO contractors to reduce costs, while highly qualified management focuses on developing life-saving medicines for immunodeficient patients.

ALVR AlloVir Inc: Rasio rega marang prakiraan pendapatan ing interval 04.07.2022 - 13.11.2026

allovir.com (ALVR) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:

Rega saham AlloVir|ALVR - Prakiraan konsensus analis

- data kapitalisasi bursa:

Nilai pasar ALVR|ALVR - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham AlloVir|ALVR - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku allovir.com|ALVR - Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- data bathi bisnis lan rasio investasi:

ALVR - Asil keuangan resik|Bathi sing dikarepake AlloVir, Inc.|ALVR - Pangali rega marang bathi|Pangali Forward P/E AlloVir|ALVR - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ALVR|ALVR - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) AlloVir|ALVR - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan allovir.com|ALVR - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep AlloVir, Inc.

- indikator pendapatan dodolan lan penghasilan bisnis:

ALVR - Pendapatan perusahaan|Prakiraan pendapatan perusahaan AlloVir|ALVR - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang prakiraan pendapatan ALVR

Analisis komprehensif perusahaan:ALVR (AlloVir Bio)

AlloVir, Inc. (ALVR) represents a biotech asset in a state of stagnation due to the suspension of several clinical trials. By analyzing the trend of the forward P/S ratio, an investor assesses the company's market value relative to projected revenue, which allows for the identification of business overvaluation or undervaluation during the waiting period for new development strategies through 2026 and filters out short-term market manipulations.

Pesaing wigati

Multiplikator Forward P/S GILD (Gilead Sciences)|Multiplikator Forward P/S Cidara Therapeutics Corp CDTX|NVAX - Rasio rega marang prakiraan pendapatan|CVAC: Rasio rega marang prakiraan pendapatan|Valneva SE (VALN) - Rasio rega marang prakiraan pendapatan|VIR (vir.bio) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan SIGA Technologies|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Emergent BioSolutions Inc EBS|Multiplikator forward rega marang pendapatan AVIR (Atea Pharmaceuticals Inc)|Rasio rega marang prakiraan pendapatan IVVD (invivyd.com)|Multiplikator Forward P/S ENTA (Enanta Pharmaceuticals)|Rasio kapitalisasi marang dodolan sing dikarepake inovio.com (INO)|HLVX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan KLRS (Kalaris Therapeutics Inc.)|DYAI (dyadic.com) - Multiplikator forward rega marang pendapatan|NanoViricides - Rega forward marang dodolan|TLPH (Talphera, Inc.) - Multiplikator Forward P/S|cocrystalpharma.com (COCP) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Traws Pharma, Inc. (TRAW)|dwtx.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S QLGN (Qualigen)|VBIV - Multiplikator forward rega marang pendapatan|VIRI: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Vaxart, Inc. VXRT